Cholinesterase inhibitors for dementia with Lewy bodies

Wild, Rebecca; Pettit, Tor; Burns, Alistair

doi:10.1002/14651858.cd003672

Cited by 64 publications

(35 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These effects are probably due to the specific selection of patients that were included in the present study. Although a worsening of parkinsonism, especially tremor, due to the use of CEIs has been described, we found no significant difference in the change of UPDRS scores over 6 months' treatment between the two groups [44,45] .…”

Section: Discussioncontrasting

confidence: 77%

Identification of Responders to Rivastigmine: A Prospective Cohort Study

Lemstra¹,

Kuiper²,

Schmand³

et al. 2007

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Background: Although the overall effects of cholinesterase inhibitors (CEIs) are limited, there could be a subpopulation of patients who experience unequivocal benefit. This study aimed to describe a clinical profile based on a combination of specific neuropsychological test scores and clinical symptoms associated with a favourable response to rivastigmine. Methods: A prospective cohort study was conducted in 53 patients who started rivastigmine treatment. Neuropsychological evaluation was performed at baseline and 6 months of treatment. Patients were labelled responders and non-responders based on change scores after 6 months in 3 clinical domains: cognition, activities of daily living and behaviour. Results: After 6 months 19 responders and 15 non-responders were identified. Variability in reaction time and Continuous Performance Test (CPT) scores differed significantly at baseline between groups. A previously defined cluster of 4 items of the Neuropsychiatric Inventory was correlated with therapeutic response. Conclusion: These findings suggest that patients who respond well to CEI therapy can be identified by deficits in attention, combined with a cluster of behavioural symptoms, including hallucinations, apathy, anxiety and psychomotor disturbances. This may constitute the clinical profile of cholinergic deficiency. Further prospective studies in larger populations are warranted to investigate whether this profile can be used to select patients who will benefit from CEIs.

show abstract

Section: Discussioncontrasting

confidence: 77%

Identification of Responders to Rivastigmine: A Prospective Cohort Study

Lemstra¹,

Kuiper²,

Schmand³

et al. 2007

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

show abstract

“…However the evidence appears to be weak. 8 Robust trials are needed in determining the efficacy of rivastigmine and other cholinesterase inhibitors in this disorder.…”

Section: Parkinson's Disease Dementia and Lewy Body Dementiamentioning

confidence: 99%

Management of dementia: review of evidence

Ratnatunge

Silva

2016

J of Cey Coll of Phy

View full text Add to dashboard Cite

“…Il est montré en intention de traiter une tendance à l'amélioration des hallucinations et des délires. La conclusion en 2006 de la Cochrane Database est qu'il ne sort de la littérature aucune information convaincante quant à l'efficacité des IACE dans la démence avec corps de Lewy [39].…”

Section: Des Interrogations Sur La Tolérance Au Long Coursunclassified